The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics
of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa …

Antiplatelet therapy has been successful in reducing mortality and morbidity in acute
myocardial infarction. Recent advances in understanding the molecular basis of the role of …

Background This guideline focuses on long-term administration of antithrombotic drugs
designed for primary and secondary prevention of cardiovascular disease, including two …

Cardiovascular disease, particularly coronary artery dis-ease resulting from accelerated
atherosclerosis, is the leading cause of morbidity and mortality in patients with diabetes …

Diabetes mellitus is an important risk factor for a first cardiovascular event and for worse
outcomes after a cardiovascular event has occurred. This situation might be caused, at least …

BACKGROUND: Although transradial percutaneous coronary intervention (TRPCI) is widely
applied for percutaneous procedures, its safety in the setting of ST-segment elevation …

Aims Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition
compared with non-diabetics following P2Y12 receptor blockade. Whether inhibition of …

BACKGROUND: Cilostazol has been widely used to prevent peripheral vascular events, and
its antiplatelet mechanisms may different from aspirin and clopidogrel. We hypothesized that …

Cardiovascular disease is the leading cause of morbidity and mortality in patients with
diabetes (1). The concomitant presence of multiple classical cardiovascular risk factors in …

The hierarchy of evidence based medicine postulates that systematic reviews of
homogenous randomized trials represent one of the uppermost levels of clinical evidence …